Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424099 | 1.00 | NPSR1 (0.47) | NPSR1POLBTSHRSMN1; SMN2FKBP5 | |
| SCHEMBL12424097 | 0.95 | FKBP5 (0.47) | NPSR1POLBTSHRSMN1; SMN2FKBP5 | |
| SCHEMBL13614085 | 0.87 | DPP4 (0.47) | NPSR1POLBTSHRSMN1; SMN2FKBP5 | |
| SCHEMBL4578857 | 0.86 | NPSR1 (0.50) | NPSR1POLBTSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL4578862 | 0.86 | NPSR1 (0.50) | NPSR1POLBTSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL21581710 | 0.86 | NPSR1 (0.44) | NPSR1POLBTSHRSMN1; SMN2FKBP5 | |
| SCHEMBL3279377 | 0.85 | P2RX7 (0.51) | NPSR1POLBTSHRSMN1; SMN2FKBP5 | |
| SCHEMBL617286 | 0.85 | NPSR1 (0.48) | NPSR1POLBTSHRSMN1; SMN2FKBP5 | |
| SCHEMBL2835654 | 0.85 | NPSR1 (0.48) | NPSR1POLBTSHRSMN1; SMN2FKBP5 | |
| SCHEMBL17462960 | 0.84 | NPSR1 (0.43) | NPSR1POLBTSHRSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | PSMC4, PSMB6, EPOR | NPSR1 1908/4885POLB 2096/4885TSHR 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.